Table 6.

Cox model measured hazard ratios and 95% confidence interval of stroke associated with sex, age, and comorbidity restricted on uricosuric agents after propensity-score matching.

Variable	Event	PY	IR	cHR (95%CI)	aHR (95%CI)
MATCHED COHORT
Non-users (n = 2,036)	100	9,137	1.1	1 (ref)	1 (ref)
Users (n = 1,454)	51	6,785	0.8	0.68 (0.49, 0.96)*	0.65 (0.46, 0.91)*
CUMULATIVE DURATION OF THERAPY (MONTHS)
Non-users	100	9,137	1.1	1 (ref)	1 (ref)
≦1	12	1,737	0.7	0.64 (0.35, 1.17)	0.71 (0.39, 1.32)
1–5	22	2,228	1.0	0.9 (0.57, 1.44)	0.87 (0.54, 1.4)
>5	17	2,820	0.6	0.54 (0.32, 0.9)*	0.43 (0.26, 0.73)**
P for trend				0.03	0.003
MONTHLY AVERAGE DAILY DOSES OF URATE-LOWERING THERAPY
Non-users	100	9,137	1.1	1 (ref)	1 (ref)
≦0.5	16	2,179	0.7	0.67 (0.39, 1.13)	0.54 (0.32, 0.93)*
0.5–0.8	8	1,537	0.5	0.47 (0.23, 0.96)*	0.42 (0.2, 0.87)*
>0.8	27	3,069	0.9	0.8 (0.53, 1.23)	0.84 (0.54, 1.29)
P for trend				0.1	0.1

IR, incidence rate, per 100 person-years; PY, person-years; CI, confidence interval; cHR, crude hazard ratio; aHR, adjusted hazard ratio, controlling for sex, age, area, every comorbidity, and drug in Table 2;

^*P < 0.05,

^**P < 0.01, and

^***P < 0.001.